Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study
Open accessAbstract
Objectives: The Janus kinase (JAK) inhibitor baricitinib may block viral entry into pneumocytes and prevent cytokine storm in patients with SARS-CoV-2 pneumonia. We aimed to assess whether baricitinib improved pulmonary function in patients treated with high-dose corticosteroids for moderate to severe SARS-CoV-2 pneumonia. Methods: This observational study enrolled patients with moderate to severe SARS-CoV-2 pneumonia [arterial oxygen partial pressure (PaO2)/fraction of inspired oxygen (FiO2) <200 mmHg] who received lopinavir/ritonavir and HCQ plus either corticosteroids (CS group, n = 50) or corticosteroids and baricitinib (BCT-CS group, n = 62). The primary end point was the change in oxygen saturation as measured by pulse oximetry (SpO2)/FiO2 from hospitalization to discharge. Secondary end points included the proportion of patients requiring supplemental oxygen at discharge and 1 month later. Statistics were adjusted by the inverse propensity score weighting (IPSW). Results: A greater improvement in SpO2/FiO2 from hospitalization to discharge was observed in the BCT-CS vs CS group (mean differences adjusted for IPSW, 49; 95% CI: 22, 77; P < 0.001). A higher proportion of patients required supplemental oxygen both at discharge (62.0% vs 25.8%; reduction of the risk by 82%, OR adjusted for IPSW, 0.18; 95% CI: 0.08, 0.43; P < 0.001) and 1 month later (28.0% vs 12.9%, reduction of the risk by 69%, OR adjusted for IPSW, 0.31; 95% CI: 0.11, 0.86; P = 0.024) in the CS vs BCT-CS group. Conclusions: . In patients with moderate to severe SARS-CoV-2 pneumonia a combination of baricitinib with corticosteroids was associated with greater improvement in pulmonary function when compared with corticosteroids alone. Trial registration: European Network of Centres for Pharmacoepidemiology and Pharmacovigilance, ENCEPP (EUPAS34966, http://www.encepp.eu/encepp/viewResource.htm? id = 34967)
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Positive anecdotal reports support targeted antagonists against interleukin-1, granulocyte-macrophage colony-stimulating factor, and JAK1 and JAK2 in patients with Covid-19.
“Further support comes from positive anecdotal reports of targeted antagonists against interleukin-1, granulocyte–macrophage colony-stimulating factor, and JAK1 and JAK2 in patients with Covid-19.102-105”
From Cytokine storm (2020) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020 · see citing works
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61602-x · Cited by 21,320 · see citing works
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477 · see citing works
Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report
Horby, P., Lim, W. S., Emberson, J., Mafham, M., Bell, J., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., et al. (2020) · doi:10.1101/2020.06.22.20137273 · Cited by 11,475 · see citing works
Austin, P. C., & Stuart, E. A. (2015) · Statistics in Medicine · doi:10.1002/sim.6607 · Cited by 4,495 · see citing works
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19
Wichmann, D., Sperhake, J., Lütgehetmann, M., Steurer, S. A., Edler, C., Heinemann, A., Heinrich, F., Mushumba, H., Kniep, I., Schröder, A. S., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-2003 · Cited by 2,271 · see citing works
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
Russell, C. D., Millar, J. E., & Baillie, J. K. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30317-2 · Cited by 2,016 · see citing works
ISTH interim guidance on recognition and management of coagulopathy in COVID‐19
Thachil, J. V., Tang, N., Gando, S., Falanga, A., Cattaneo, M., Levi, M. M., Clark, C., & Iba, T. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14810 · Cited by 1,957 · see citing works
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechsle, O., Phelan, A., Rawling, M., Savory, E., & Stebbing, J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30304-4 · Cited by 1,456 · see citing works
D‐dimer levels on admission to predict in‐hospital mortality in patients with Covid‐19
Zhang, L., Yan, X., Fan, Q., Liu, H., Liu, X., Liu, Z., & Zhang, Z. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14859 · Cited by 1,347 · see citing works
Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome
Arabi, Y. M., Mandourah, Y., Al-Hameed, F. M., Sindi, A., Almekhlafi, G. A., Hussein, M. A., Jose, J., Pinto, R. L., Al‐Omari, A., Kharaba, A. M., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201706-1172oc · Cited by 1,122 · see citing works
COVID-19: combining antiviral and anti-inflammatory treatments
Stebbing, J., Phelan, A., Griffin, I., Tucker, C., Oechsle, O., Smith, D., & Richardson, P. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30132-8 · Cited by 1,117 · see citing works
Rice, T. W., Wheeler, A. P., Bernard, G. R., Hayden, D. L., Schoenfeld, D., & Ware, L. B. (2007) · CHEST Journal · doi:10.1378/chest.07-0617 · Cited by 831 · see citing works
Baricitinib in Patients with Refractory Rheumatoid Arthritis
Genovese, M. C., Kremer, J. M., Zamani, O., Ludivico, C. L., Krogulec, M., Xie, L., Beattie, S. D., Koch, A. E., Cardillo, T. E., Rooney, T. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507247 · Cited by 632 · see citing works
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19
Wichmann, D. (2020) · Annals of Internal Medicine · doi:10.7326/l20-1206 · Cited by 630 · see citing works
On the use of corticosteroids for 2019-nCoV pneumonia
Shang, L., Zhao, J., Hu, Y., Du, R., & Cao, B. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30361-5 · Cited by 604 · see citing works
IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes
Channappanavar, R., Fehr, A. R., Zheng, J. H., Wohlford-Lenane, C., Abrahante, J. E., Mack, M., Sompallae, R. R., McCray, P. B., Meyerholz, D. K., & Perlman, S. M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126363 · Cited by 556 · see citing works
Xu, K., Chen, Y., Yuan, J., Yi, P., Ding, C., Wu, W., Li, Y., Ni, Q., Zou, R., Li, X., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa351 · Cited by 501 · see citing works
Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19
Fadel, R. A., Morrison, A. R., Vahia, A. T., Smith, Z., Chaudhry, Z., Bhargava, P., Miller, J. B., Kenney, R. M., Alangaden, G. J., Ramesh, M. S., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa601 · Cited by 461 · see citing works
COVID-19 infection and rheumatoid arthritis: Faraway, so close
Favalli, E. G., Ingegnoli, F., De Lucia, O., Cincinelli, G., Cimaz, R., & Caporali, R. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102523 · Cited by 454 · see citing works
Toh, C., & Hoots, W. K. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02313.x · Cited by 380 · see citing works
Yang, Z., Liu, J., Zhou, Y., Zhao, Q., Zhao, Q., & Liu, J. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.062 · Cited by 361 · see citing works
Marietta, M., Ageno, W., Artoni, A., Candia, E. D., Gresele, P., Marchetti, M., Marcucci, R., & Tripodi, A. (2020) · Blood transfusion · doi:10.2450/2020.0083-20 · Cited by 348 · see citing works
Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients
Stebbing, J., Krishnan, V., de Bono, S., Ottaviani, S., Casalini, G., Richardson, P. J., Monteil, V., Lauschke, V. M., Mirazimi, A., Youhanna, S. C., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012697 · Cited by 291 · see citing works
Rojo, J. M. C., Santos, J. M. A., Millán-Núñez-Cortés, J., Lumbreras, C., Rincón, J. M. R., Roy‐Vallejo, E., Artero, A., Arnalich, F., Bruñén, J. M. G., Vargas-Núñez, J. A., et al. (2020) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2020.07.003 · Cited by 271 · see citing works
JAK Inhibition as a New Treatment Strategy for Patients with COVID-19
Seif, F., Aazami, H., Khoshmirsafa, M., Kamali, M., Mohsenzadegan, M., Pornour, M., & Mansouri, D. (2020) · International Archives of Allergy and Immunology · doi:10.1159/000508247 · Cited by 198 · see citing works
Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study
Cantini, F., Niccoli, L., Nannini, C., Matarrese, D., Natale, M. E. D., Lotti, P., Aquilini, D., Landini, G., Cimolato, B., Pietro, M. A. D., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.06.052 · Cited by 174 · see citing works
Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers
Rello, J., Storti, E., Belliato, M., & Serrano, R. (2020) · European Respiratory Journal · doi:10.1183/13993003.01028-2020 · Cited by 158 · see citing works
Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis
Mogul, A., Corsi, K., & McAuliffe, L. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019839650 · Cited by 148 · see citing works
Verden, A., Dimbil, M., Kyle, R. F., Overstreet, B. M., & Hoffman, K. B. (2017) · Drug Safety · doi:10.1007/s40264-017-0622-2 · Cited by 138 · see citing works
Tanaka, Y., Emoto, K., Cai, Z., Aoki, T., Schlichting, D. E., Rooney, T. P., & Macias, W. L. (2016) · The Journal of Rheumatology · doi:10.3899/jrheum.150613 · Cited by 124 · see citing works
Ozoliņa, A., Šarkele, M., Sabeļņikovs, O., Šķesters, A., Jaunalksne, I., Serova, J., Ievins, T., Bjertnæs, L. J., & Vanags, I. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2016.00064 · Cited by 77 · see citing works
Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases
Mayence, A., & Eynde, J. J. V. (2019) · Pharmaceuticals · doi:10.3390/ph12010037 · Cited by 56 · see citing works
The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib.
Choy, E., Miceli‐Richard, C., González-Gay, M. Á., SINIGAGLIA, L., Schlichting, D. E., Meszaros, G., de la Torre, I., & Schulze‐Koops, H. (2019) · PubMed · Cited by 53 · see citing works
Brink, H. R. V. D., Wijk, M. J. G. V., Geertzen, R. G. M., & Bijlsma, J. W. J. (1994) · PubMed · Cited by 29 · see citing works
Clinical Early Warning Scores: New Clinical Tools in Evolution
Doyle, D. J. (2018) · The Open Anesthesia Journal · doi:10.2174/2589645801812010026 · Cited by 27 · see citing works
COVID-19: an unexpected indication for anti-rheumatic therapies?
Lucchino, B., Franco, M. D., & Conti, F. (2020) · Lara D. Veeken · doi:10.1093/rheumatology/keaa194 · Cited by 13 · see citing works
Flagged first, then by citations
1 of the 38 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Rice TW, Wheeler AP, Bernard GR et al. Comparison of the SpO 2 /FIO 2 ratio and the PaO 2 /FIO 2 ratio in patients with acute lung injury or ARDS. Chest 2007;132:410-7.
- Xu K, Chen Y, Yuan J et al. Factors associated with prolonged viral RNA shedding in patients with COVID- 19. Clin Infect Dis 2020;71:799-806.
Cited by
Sorted by citations
Fajgenbaum, D. C., & June, C. H. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2026131 · Cited by 3,196 · see citing works
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
Kalil, A. C., Patterson, T. F., Mehta, A. K., Tomashek, K. M., Wolfe, C. R., Ghazaryan, V., Marconi, V. C., Ruiz-Palacios, G. M., Hsieh, L. L., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2031994 · Cited by 1,840 · see citing works
The signal pathways and treatment of cytokine storm in COVID-19
Yang, L., Xie, X., Tu, Z., Fu, J., Xu, D., & Zhou, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00679-0 · Cited by 599 · see citing works
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia
Guimarães, P. O., Quirk, D. M., Furtado, R. H. D. M., Maia, L. N., Saraiva, J. F. K., Antunes, M. D. O., Filho, R. K., Junior, V. M., Soeiro, A. M., Tognon, A. P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101643 · Cited by 434 · see citing works
Therapeutic potential of PANoptosis: innate sensors, inflammasomes, and RIPKs in PANoptosomes
Pandeya, A., & Kanneganti, T. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.10.001 · Cited by 314 · see citing works
Bhimraj, A., Morgan, R. L., Shumaker, A. H., Baden, L. R., Cheng, V. C., Edwards, K. M., Gallagher, J. C., Gandhi, R. T., Muller, W. J., Nakamura, M., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac724 · Cited by 215 · see citing works
Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality
Que, Y., Hu, C., Wan, K., Hu, P., Wang, R., Luo, J., Li, T., Ping, R., Hu, Q., Sun, Y., et al. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1884248 · Cited by 167 · see citing works
Kandhaya‐Pillai, R., Yang, X., Tchkonia, T., Martin, G. M., Kirkland, J. L., & Oshima, J. (2022) · Aging Cell · doi:10.1111/acel.13646 · Cited by 119 · see citing works
Fagni, F., Simón, D., Taşçılar, K., Schönau, V., Sticherling, M., Neurath, M. F., & Schett, G. A. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00247-2 · Cited by 107 · see citing works
Morris, G., Bortolasci, C. C., Puri, B. K., Marx, W., O'Neil, A. E., Athan, E., Walder, K. R., Berk, M., OLIVE, L. S., Carvalho, A. F., et al. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155593 · Cited by 97 · see citing works
Fernandez‐Ruiz, R., Paredes, J. L., & Niewold, T. B. (2020) · Translational research · doi:10.1016/j.trsl.2020.12.007 · Cited by 92 · see citing works
JAK inhibitors: Ten years after
Spinelli, F. R., Meylan, F., O’Shea, J. J., & Gadina, M. (2021) · European Journal of Immunology · doi:10.1002/eji.202048922 · Cited by 88 · see citing works
Langford, B. J., So, M., Leung, V., Raybardhan, S., Lo, J., Kan, T., Leung, F., Westwood, D. J., Daneman, N., MacFadden, D. R., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.11.008 · Cited by 85 · see citing works
JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis
Chen, C., Wang, J., Li, H., Yuan, L.-T., Gale, R. P., & Liang, Y. (2021) · Leukemia · doi:10.1038/s41375-021-01266-6 · Cited by 87 · see citing works
Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions
Jiang, Y., Zhao, T., Zhou, X., Yu, X., Gutiérrez‐Castrellón, P., & Ma, X. (2022) · MedComm · doi:10.1002/mco2.154 · Cited by 72 · see citing works
Baricitinib: From Rheumatoid Arthritis to COVID‐19
Assadiasl, S., Fatahi, Y., Mosharmovahed, B., Mohebbi, B., & Nicknam, M. H. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1874 · Cited by 66 · see citing works
Yin, J., Li, C., Ye, C., Ruan, Z., Liang, Y., Li, Y., Wu, J., & Luo, Z. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.01.026 · Cited by 66 · see citing works
Suárez‐García, I., Perales-Fraile, I., García, A. G., Blanco, A. M., Manzano, L., Fabregate, M., Díez‐Manglano, J., Aizpuru, E. F., Arnalich, F., García, A. G., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255524 · Cited by 57 · see citing works
Boswellic acids/Boswellia serrata extract as a potential COVID-19 therapeutic agent in the elderly
Gomaa, A. A., Mohamed, H. S., Abd-ellatief, R. B., & Gomaa, M. A. (2021) · Inflammopharmacology · doi:10.1007/s10787-021-00841-8 · Cited by 54 · see citing works
Current Status of Baricitinib as a Repurposed Therapy for COVID-19
Saber-Ayad, M. M., Hammoudeh, S. M., Abu‐Gharbieh, E., Hamoudi, R., Tarazi, H., Al‐Tel, T. H., & Hamid, Q. A. (2021) · Pharmaceuticals · doi:10.3390/ph14070680 · Cited by 52 · see citing works
Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of COVID-19
Naik, R. R., Shakya, A. K., Aladwan, S., & El‐Tanani, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.806568 · Cited by 50 · see citing works
Janus kinase inhibitors for the treatment of COVID-19
Kramer, A., Prinz, C., Fichtner, F., Fischer, A.-L., Thieme, V., Grundeis, F., Spagl, M., Seeber, C., Piechotta, V., Metzendorf, M., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015209 · Cited by 51 · see citing works
Lin, Z., Niu, J., Xu, Y., Qin, L., Ding, J., & Zhou, L. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27482 · Cited by 45 · see citing works
Alunno, A., Najm, A., Xavier Mariette, A., Marco, G. D., Emmel, J., Mason, L., McGonagle, D., & Machado, P. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-219725 · Cited by 45 · see citing works
Meyerowitz, E. A., Sen, P., Schoenfeld, S. R., Neilan, T. G., Frigault, M. J., Stone, J. H., Kim, A. Y., & Mansour, M. K. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1759 · Cited by 44 · see citing works
Singh, D., Bogus, M., Moskalenko, V., Lord, R. W., Moran, E. J., Crater, G., Bourdet, D. L., Pfeifer, N. D., Woo, J., Kaufman, E., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.00673-2021 · Cited by 44 · see citing works
Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies
Alexander, M. T., Luo, Y., Raimondi, G., O’Shea, J. J., & Gadina, M. (2021) · Pharmaceuticals · doi:10.3390/ph15010048 · Cited by 45 · see citing works
Combination therapies for COVID‐19: An overview of the clinical trials landscape
Akinbolade, S., Coughlan, D., Fairbairn, R., McConkey, G. A., Powell, H., Ogunbayo, O. J., & Craig, D. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15089 · Cited by 43 · see citing works
The role of antirheumatics in patients with COVID-19
Nissen, C. B., Sciascia, S., ANDRADE, D. C. O. D., Atsumi, T., Bruce, I. N., Cron, R. Q., Hendricks, O., Roccatello, D., Stach, K., Trunfio, M., et al. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00062-x · Cited by 42 · see citing works
Sharun, K., Tiwari, R., Yatoo, M. I., Natesan, S., Megawati, D., Singh, K. P., Michalak, I., & Dhama, K. (2022) · Narra J · doi:10.52225/narra.v2i3.92 · Cited by 42 · see citing works
Gatti, M., Turrini, E., Raschi, E., Sestili, P., & Fimognari, C. (2021) · Pharmaceuticals · doi:10.3390/ph14080738 · Cited by 42 · see citing works
Limen, R. Y., Sedono, R., Sugiarto, A., & Hariyanto, T. I. (2021) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1982695 · Cited by 40 · see citing works
The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19
Richardson, P. J., Robinson, B. W. S., Smith, D. P., & Stebbing, J. (2022) · Vaccines · doi:10.3390/vaccines10060951 · Cited by 43 · see citing works
COVID-19 Immunobiology: Lessons Learned, New Questions Arise
Kaklamanos, A., Belogiannis, K., Skendros, P., Gorgoulis, V. G., Vlachoyiannopoulos, P. G., & Tzioufas, A. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.719023 · Cited by 37 · see citing works
Coronavirus disease 2019 (COVID-19) and autoimmunity
Nasonov, E. L. (2021) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2021-5-30 · Cited by 40 · see citing works
Pérez-Alba, E., Nuzzolo-Shihadeh, L., Aguirre-García, G. M., Espinosa-Mora, J. E., Lecona-Garcia, J. D., Flores-Pérez, R. O., Mendoza-Garza, M., & Camacho-Ortíz, A. (2021) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2021.05.009 · Cited by 37 · see citing works
JAK inhibition as a new treatment strategy for patients with COVID-19
Huang, J., Zhou, C., Jinniu, D., & Zhou, J. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115162 · Cited by 36 · see citing works
Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review
Jain, N. K., Tailang, M., Jain, H. K., Chandrasekaran, B., Sahoo, B. M., Subramanian, A., Thangavel, N., Aldahish, A. A., Chidambaram, K., Muthumanickam, A., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1135145 · Cited by 34 · see citing works
COVID-19 illness and autoimmune diseases: recent insights
Li, J., Liu, H., Yin, X., Li, C., & Wang, J. (2021) · Inflammation Research · doi:10.1007/s00011-021-01446-1 · Cited by 32 · see citing works
Manoharan, S., & Ying, L. Y. (2023) · International Journal of Clinical Practice · doi:10.1155/2023/1068000 · Cited by 32 · see citing works
Chen, C.-Y., Chen, W., Hsu, C., Chao, C., & Lai, C. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108027 · Cited by 31 · see citing works
Baricitinib reduces 30‐day mortality in older adults with moderate‐to‐severe COVID ‐19 pneumonia
Abizanda, P., Mayo, J. M. C., Romero, M. M., Zamora, E. B. C., Sahuquillo, M. T. T., Rizos, L. R., Sánchez‐Jurado, P. M., Nievas, G. S., Escolano, C. C., Serrano, A. O., et al. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17357 · Cited by 29 · see citing works
Network analytics for drug repurposing in COVID-19
Siminea, N., Popescu, V., Martín, J. Á. S., Florea, D., Gavril, G., Gheorghe, A.-M., Iţcuş, C., Kanhaiya, K., Pacioglu, O., Popa, L. I., et al. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab490 · Cited by 29 · see citing works
Akbarzadeh-Khiavi, M., Torabi, M., Rahbarnia, L., & Safary, A. (2021) · Infection · doi:10.1007/s15010-021-01730-6 · Cited by 26 · see citing works
Roles of existing drug and drug targets for COVID-19 management
Ayele, A. G., Enyew, E. F., & Kifle, Z. D. (2021) · Metabolism Open · doi:10.1016/j.metop.2021.100103 · Cited by 24 · see citing works
Patel, N. M., Collotta, D., Aimaretti, E., Alves, G. F., Kröller, S., Coldewey, S. M., Collino, M., & Thiemermann, C. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000005571 · Cited by 24 · see citing works
Therapeutic role of immunomodulators during the COVID-19 pandemic– a narrative review
Alhajeri, H., Baron, F., Abutiban, F., Mutairi, M. A., Ali, Y., Al-Awadhi, A. M., Albasri, A., Aldei, A., Alenizi, A., Alhadhood, N., et al. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2033563 · Cited by 25 · see citing works
Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics
Chatterjee, B., & Thakur, S. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830990 · Cited by 22 · see citing works
Janus Kinase inhibitors for the treatment of hospitalized patients with COVID-19
Florescu, D. F., & Kalil, A. C. (2021) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000869 · Cited by 21 · see citing works
Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2
Xue, Y., Mei, H., Chen, Y., Griffin, J. D., Liu, Q., Weisberg, E., & Yang, J. C. (2023) · MedComm · doi:10.1002/mco2.254 · Cited by 19 · see citing works
COVID-19, what could sepsis, severe acute pancreatitis, gender differences, and aging teach us?
Gallo, C. G., Fiorino, S., Posabella, G., Antonacci, D., Tropeano, A., Pausini, E., Pausini, C., Guarniero, T., Hong, W., Giampieri, E., et al. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155628 · Cited by 17 · see citing works
Recent clinical findings on the role of kinase inhibitors in COVID-19 management
Malekinejad, Z., Baghbanzadeh, A., Nakhlband, A., Baradaran, B., Jafari, S., Bagheri, Y., Raei, F., Montazersaheb, S., & Farahzadi, R. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120809 · Cited by 18 · see citing works
An Emerging Role for Type I Interferons as Critical Regulators of Blood Coagulation
Ryan, T. A. J., & O'Neill, L. A. J. (2023) · Cells · doi:10.3390/cells12050778 · Cited by 19 · see citing works
Cellular and molecular features of COVID-19 associated ARDS: therapeutic relevance
Scaramuzzo, G., Nucera, F., Asmundo, A., Messina, R., Mari, M., Montanaro, F., Johansen, M. D., Monaco, F. L., Fadda, G., Tuccari, G., et al. (2023) · Journal of Inflammation · doi:10.1186/s12950-023-00333-2 · Cited by 17 · see citing works
Scott, T. M., Jensen, S., & Pickett, B. E. (2021) · F1000Research · doi:10.12688/f1000research.52412.1 · Cited by 12 · see citing works
Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists
Kawazoe, M., Kihara, M., & Nanki, T. (2021) · Pharmaceuticals · doi:10.3390/ph14121256 · Cited by 15 · see citing works
Effectiveness of estrogen and its derivatives over dexamethasone in the treatment of COVID-19
Parveen, D., Das, A., Amin, S., Alam, M. M., Akhter, M., Khan, M. A., Ali, R., Anwer, T., Sheikh, K. A., Azam, F., et al. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2205944 · Cited by 15 · see citing works
Cherian, J. J., Eerike, M., Bagepally, B. S., Das, S., & Panda, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1004308 · Cited by 13 · see citing works
Marín, S., Val, A. M., Peligero, M. B., Rodríguez-Bernuz, C., Pérez‐Ricart, A., Jaques, L. V., Paredes, R., Roca, J., & Quiñones, C. (2022) · Pharmaceuticals · doi:10.3390/ph15050634 · Cited by 13 · see citing works
Contemporary narrative review of treatment options for COVID ‐19
Shang, L., Lye, D. C., & Cao, B. (2021) · Respirology · doi:10.1111/resp.14106 · Cited by 11 · see citing works
Anakinra versus Baricitinib: Different Strategies for Patients Hospitalized with COVID-19
García-García, J. Á., Perez-Quintana, M., Ramos-Giráldez, C., Cebrián-González, I., Martín-Ponce, M. L., del Valle-Villagrán, J., Navarro-Puerto, M. A., Sánchez-Villegas, J., Gómez-Herreros, R., Bustos, I. M., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10174019 · Cited by 12 · see citing works
A Peek into Pandora’s Box: COVID-19 and Neurodegeneration
Chandra, A., & Johri, A. (2022) · Brain Sciences · doi:10.3390/brainsci12020190 · Cited by 12 · see citing works
Nasonov, E. L., & Korotaeva, T. V. (2022) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2022-131-148 · Cited by 12 · see citing works
Manoharan, S., & Ying, L. Y. (2022) · Respiratory Medicine · doi:10.1016/j.rmed.2022.106986 · Cited by 12 · see citing works
Tekantapeh, S. T., Ghojazadeh, M., Ghamari, A. A., Mohammadi, A., & Soleimanpour, H. (2022) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2022.2114899 · Cited by 11 · see citing works
Current Use of Baricitinib in COVID-19 Treatment and Its Future: An Updated Literature Review
Dupuis, D., Fritz, K., Ike, E., Arogundade, O., Adewara, E. O., Monday, E. O., & Ayinde, B. O. (2022) · Cureus · doi:10.7759/cureus.28680 · Cited by 10 · see citing works
Use of baricitinib in treatment of COVID‐19: a systematic review
Sampath, A., Banerjee, A., Atal, S., & Jhaj, R. (2023) · Medicinal Research Reviews · doi:10.1002/med.21951 · Cited by 9 · see citing works
Scientific evidence in the COVID-19 treatment: A comprehensive review
Iturricastillo, G., Ávalos, E., Couñago, F., & Landete, P. (2021) · World Journal of Virology · doi:10.5501/wjv.v10.i5.217 · Cited by 8 · see citing works
Immunomodulation and immunotherapeutics of COVID-19
Garg, S. S., Sharma, A., & Gupta, J. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108842 · Cited by 8 · see citing works
Vahed, S. Z., Khatibi, S. M. H., Ahmadian, E., & Ardalan, M. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112614 · Cited by 8 · see citing works
Casillas, N., Torres, A. M., Rueda, M. M., Gómez, A., Rius‐Peris, J. M., & Mateo, J. (2022) · Internal and Emergency Medicine · doi:10.1007/s11739-022-03033-6 · Cited by 8 · see citing works
JAK Inhibitors in Cytokine Storm Syndromes
Keenan, C., Albeituni, S., Nichols, K. E., & Hines, M. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-59815-9_39 · Cited by 7 · see citing works
From pandemic onset to present: five years of insights into ARDS caused by COVID-19
Ortiz‐Prado, E., Izquierdo‐Condoy, J. S., Vásconez-González, J., López‐Cortés, A., Salazar-Santoliva, C., Michay, A. R. V., Vélez-Páez, J. L., & Unigarro, L. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2507207 · Cited by 7 · see citing works
Song, W., Sun, S., Feng, Y., Liu, L., Gao, T., Xian, S., & Chen, J. (2023) · Medicine · doi:10.1097/md.0000000000036313 · Cited by 7 · see citing works
Tran, A. P., Tassone, D., Nossent, J. C., & Ding, N. S. (2022) · RMD Open · doi:10.1136/rmdopen-2022-002301 · Cited by 7 · see citing works
Molecular mechanisms of SARS-CoV-2 entry: implications for biomedical strategies
Santamaria-Castro, I., Leiva-Rebollo, R., Marín‐Wong, S., Jiménez-Guardeño, J. M., & Ortega‐Prieto, A. M. (2025) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00260-24 · Cited by 6 · see citing works
Molecular Roadmap of COVID‐19: From Viral Entry to Therapeutic Targets
Ishola, A. A., Ahmed, I. A., & Mikail, M. A. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202501534 · Cited by 6 · see citing works
Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment
Taibe, N. S., Kord, M. A., Badawy, M. A., Shytaj, I. L., & ElHefnawi, M. (2022) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666221132736 · Cited by 6 · see citing works
Banerjee, A., Goswami, R. P., & Chatterjee, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-82139-x · Cited by 6 · see citing works
Jurenka, J., Nagyová, A., Dababseh, M., Mihalov, P., Stankovič, I., Boža, V., Kravec, M., Palkovič, M., Čaprnda, M., & Sabaka, P. (2022) · Infectious Disease Reports · doi:10.3390/idr14060100 · Cited by 5 · see citing works
Role of baricitinib in COVID-19 patients: A systematic review and meta-analysis
Thakur, M., Babu, A., Khatik, G. L., Datusalia, A. K., Khatri, R., & Kumar, A. (2023) · World Journal of Meta-Analysis · doi:10.13105/wjma.v11.i4.125 · Cited by 5 · see citing works
PANoptosis in life and death across cell types: From innate immunity to therapeutic implications
Zengeler, K. E., Tweedell, R. E., & Kanneganti, T. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.06.007 · Cited by 4 · see citing works
Ferro, F., Rocca, G. L., Elefante, E., Italiano, N., Moretti, M., Talarico, R., Pelati, E., Valentini, K., Baldini, C., Mozzo, R., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137273 · Cited by 4 · see citing works
Gopcsa, L., Bobek, I., Bekő, G., Lakatos, B., Molnár, E., Réti, M., Remenyi, P. P., Sinkó, J., Szlávik, J., Tatai, G., et al. (2021) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/030.2021.01620 · Cited by 4 · see citing works
Tufan, A., & Cerinic, M. M. (2021) · Turkish Journal of Medical Sciences · doi:10.3906/sag-2110-179 · Cited by 5 · see citing works
Oda, N., Miyoshi, K., Morichika, D., Beika, Y., Taki, T., Mitani, R., Okada, T., & Takata, I. (2021) · Clinical Case Reports · doi:10.1002/ccr3.4459 · Cited by 4 · see citing works
Hospital capacity and admission rate may be a factor of importance to mortality in COVID-19
Martínez, J. J. A., del Pozo, J. S. G., Lamas, C., Mellinas, G. P., Castillo, S. G., Cifuentes, M. M., & Pinés, P. J. (2021) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2021.2001565 · Cited by 4 · see citing works
COVID-19 Drug Repositioning: Present Status and Prospects
Mohanty, C., Vinod, C., Acharya, S., & Mahapatra, N. (2021) · Studies in systems, decision and control · doi:10.1007/978-3-030-72834-2_19 · Cited by 3 · see citing works
Tanaka, H., Chubachi, S., Namkoong, H., Sato, Y., Asakura, T., Lee, H., Azekawa, S., Otake, S., Nakagawara, K., Fukushima, T., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad311 · Cited by 3 · see citing works
SARS-CoV-2 Virus Manifestations in the Gastrointestinal Tract: Therapeutic Implications
Jefremow, A., & Neurath, M. F. (2020) · Visceral Medicine · doi:10.1159/000513180 · Cited by 3 · see citing works
Janus kinases inhibitors for coronavirus disease-2019: A pairwise and Bayesian network meta-analysis
Niu, J., Lin, Z., He, Z., Yang, X.-J., Qin, L., Feng, S., Guan, L., Zhou, L., & Chen, R. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.973688 · Cited by 3 · see citing works
Neurovascular complications of antiphospholipid syndrome: a narrative review
Mendes, G. N. N., de Morais, A. B. C. G., Gioia, L. C., Jacquin, G., Poppe, A. Y., Soga, F. H., & de Andrade, J. B. C. (2024) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0044-1793932 · Cited by 2 · see citing works
Yue, L., & Yan, Y. (2023) · Cellular and Molecular Biology · doi:10.14715/cmb/2023.69.15.27 · Cited by 2 · see citing works
Oral anti-COVID-19 drugs that were recently evaluated by FDA or EMA: a review
Lorenz, D., & Pawliczak, R. (2022) · Alergologia Polska - Polish Journal of Allergology · doi:10.5114/pja.2022.114394 · Cited by 2 · see citing works
JAK Inhibitors as a Barrier to the Destructive Cytokine Storm in COVID-19
Saeedi‐Boroujeni, A., & Asadi-Samani, M. (2022) · Current Drug Research Reviews · doi:10.2174/2589977514666220304203816 · Cited by 2 · see citing works
Lin, Z., Niu, J., Xu, Y., Qin, L., Ding, J., & Zhou, L. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3929406 · Cited by 2 · see citing works
Antirheumatic drugs and COVID-19: frustrations and hopes
Aronova, E. S., & Belov, B. S. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-10-134-139 · Cited by 1 · see citing works
Baricitinib or Tocilizumab? Treatment of Patients Hospitalized With Severe COVID-19*
Cawcutt, K. A., & Kalil, A. C. (2023) · Critical Care Medicine · doi:10.1097/ccm.0000000000005757 · Cited by 1 · see citing works
Could Pomegranate Fight against SARS-CoV-2?
Elnawasany, S. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96423 · Cited by 1 · see citing works
Özen, S., Gülhan, B., Yüksek, S. K., Güney, A. Y., Erat, T., Yahşi, A., Güneş, Ö., Güder, L., Mustafaoğlu, Ö., Bayraktar, P., et al. (2022) · Journal of Pediatric Infectious Diseases · doi:10.1055/s-0042-1759529 · Cited by 1 · see citing works
- Authors
- Rodriguez-Garcia, J. L., Sanchez-Nievas, G., Arevalo-Serrano, J., Garcia-Gomez, C., Jimenez-Vizuete, J. M., & Martinez-Alfaro, E.
- Affiliations
- Internal Medicine
- Rheumatology, General University Hospital of Albacete, Albacete
- Internal Medicine, Principe de Asturias University Hospital, Alcala de Henares
- Pharmacy
- Anaesthesiology
- Infectious Diseases, General University Hospital of Albacete, Albacete, Spain
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-10-06
- Volume
- 60
- Issue
- 1
- Pages
- 399-407
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- PMC
- PMC7665718
- OpenAlex
- W3089416670
- Cited by
- 112
- References
- 38
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 15 · 2022: 35 · 2021: 49 · 2020: 5
- FWCI
- 3.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Lara D. Veeken (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory Support and Mechanisms
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- baricitinib, COVID-19 pneumonia, COVID-19 pandemic, corticosteroids, JAK inhibitors, lung function, oxygen saturation, supplemental oxygen requirement, lopinavir/ritonavir, hydroxychloroquine, combination therapy, cytokine storm, inverse propensity weighting, pharmacoepidemiology, pharmacovigilance
- MeSH terms
- Interferon beta-1b, Janus Kinase Inhibitors, COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Aged, Hypoxia, Antiviral Agents, Azetidines, Drug Combinations, Drug Therapy, Combination, Endothelium, Vascular, Enzyme Inhibitors, Female, Fibrin Fibrinogen Degradation Products, Glucocorticoids, Humans, Hydroxychloroquine, Immunologic Factors, Lung, Male, Methylprednisolone, Middle Aged, Oximetry, Oxygen Inhalation Therapy, Prospective Studies, Purines, Pyrazoles, Severity of Illness Index, Sulfonamides, Cohort Studies, Immunoglobulins, Intravenous, Ritonavir, Lopinavir
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
